Long-term follow-up of a randomized phase II study of Cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021)

Japanese Journal of Clinical Oncology

Volumn 42, Issue 9, 2012, Pages 807-812

  Nishimura, Yasumasa ^a   Hiraoka, Masahiro ^b   Koike, Ryuta ^a   Nakamatsu, Kiyoshi ^a   Itasaka, Satoshi ^b   Kawamura, Masashi ^c   Negoro, Yoshiharu ^d   Araki, Norio ^e   Ishikawa, Hitoshi ^f   Fujii, Takashi ^g   Mitsuhashi, Norio ^h  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Nara Social Insurance Hospital   (Japan)

^d FUKUI PREFECTURAL HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^f GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Esophageal cancer; Hypothyroidism; Late toxicities; Secondary malignancy

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER STAGING; CARDIOTOXICITY; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG SAFETY; ESOPHAGUS CANCER; ESOPHAGUS DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPOTHYROIDISM; LOW DRUG DOSE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OVERALL SURVIVAL; PATIENT MONITORING; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA DISEASE; PLEURA EFFUSION; PNEUMOTHORAX; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECOND CANCER; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; HYPOTHYROIDISM; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84865530721     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys112     Document Type: Article

References (20)

1. Al-Sarraf M, Herskovic A, Martz K, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an Intergroup study. J Clin Oncol 1997;15:277-84.
2. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-7.
3. Smith TJ, Ryan LM, Douglass HO, Jr, et al., Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:269-76.
4. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-74.
5. Nishimura Y, Suzuki M, Nakamatsu K, et al. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys 2002;53:134-9.
6. Koike R, Nishimura Y, Nakamatsu K, et al. Concurrent chemoradiotherapy for esophageal cancer with malignant fistula. Int J Radiat Oncol Biol Phys 2008;70:1418-22.
7. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999;17:2915-21.
8. Sakai K, Inakoshi H, Sueyama H, et al. Concurrent radiotherapy and chemotherapy with protracted continuous infusion of 5-fluorouracil in inoperable esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 1995;31:921-7.
9. Sasamoto R, Sakai K, Inakoshi H, et al. Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloro-platinum (CDDP). Int J Clin Oncol 2007;12:25-30.
10. Hsu C, Yeh K, Lui L, et al. Concurrent chemoradiotherapy for locally advanced esophageal cancer; a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil. Anticancer Res 1999;19:4463-8.
11. Nishimura Y, Koike R, Ogawa K, et al. Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey. Int J Clin Oncol 2012;17:48-54.
12. Nishimura Y, Mitsumori M, Hiraoka M, et al. A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021). Radiother Oncol 2009;92:260-5.
13. Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 2011;81:684-90.
14. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003;21:2697-702.
15. Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 2008;70:707-14.
16. Bhandare N, Kennedy L, Malyapa RS, et al. Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 2007;68:1131-9.
17. Citrin D, Mansueti J, Likhacheva A, et al. Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;74:1040-6.
18. Tong DK, Law S, Kwong DL, et al. Current management of cervical esophageal cancer. World J Surg 2011;35:600-7.
19. Mimura N, Tsujimura H, Ise M, et al. Therapy-related leukemia following chemoradiotherapy for esophageal cancer. Eur J Haematol 2010;85:353-7.
20. Chang H, Liaw CC, Chang HK. Therapy-related acute myeloid leukemia after concurrent chemoradiotherapy for esophageal cancer: report of two cases. Tumori 2009;95:371-3.